Current Report Filing (8-k)
August 26 2020 - 04:32PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report: August 26, 2020
(Date of earliest event reported)
COHBAR,
INC.
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
Delaware
|
|
001-38326
|
|
26-1299952
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1455 Adams Drive, Suite 2050
Menlo Park, CA 94025
(Address of principal executive offices
and zip code)
(650) 446-7888
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered
pursuant to Section 12(b) of the Act:
Title of each
class
|
|
Trading Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock
|
|
CWBR
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
COHBAR, INC.
FORM 8-K
Item 1.01.
|
Entry into a Material Definitive
Agreement.
|
On August 26,
2020, CohBar, Inc. (“CohBar”) entered into an underwriting agreement (the “Underwriting
Agreement”) with Roth Capital Partners, LLC, as representative of the several underwriters named therein (the “Underwriters”),
pursuant to which CohBar agreed to issue and sell an aggregate of 12,300,000 units (the “Units”) consisting
of one share of its common stock (the “Common Stock”), par value $0.001 per share, and one warrant to
purchase 0.75 of one share of Common Stock at an exercise price of $1.44 (the “Warrants”), to
the Underwriters (the “Offering”) at the public offering price of $1.22 per Unit, less underwriting
discounts and commissions. The Warrants are exercisable for five years from the closing date of the offering. Pursuant to the
Underwriting Agreement, CohBar has also granted the Underwriters a 30-day option to purchase up to an additional 15%
of the aggregate number of shares of Common Stock and/or 15% of the aggregate number of Warrants offered (the “Option”).
The Underwriting Agreement contains customary representations and warranties, conditions to closing, market standoff provisions,
termination provisions and indemnification obligations, including for liabilities under the Securities Act of 1933, as amended
(the “Securities Act”). The Offering is being made pursuant to the shelf registration statement on Form S-3 (File No. 333-221724) that
was filed by CohBar with the Securities and Exchange Commission (“SEC”) on November 22, 2017 and declared
effective by the SEC on December 1, 2017, and a related prospectus supplement.
CohBar estimates
that the net proceeds from the Offering will be approximately $13.6 million, after deducting underwriting discounts
and commissions and estimated Offering expenses, and assuming no exercise of the Option. CohBar intends to use the net proceeds
from the Offering, together with its existing cash resources, for general corporate purposes, which may include funding preclinical
and clinical development of CohBar’s peptides, increasing its working capital, operating expenses and capital expenditures.
CohBar expects the Offering to close on August 28, 2020, subject to customary closing conditions.
The Underwriting
Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K, and the foregoing description of the terms of the Underwriting
Agreement is qualified in its entirety by reference to such exhibit. The form of Warrant is filed as Exhibit 4.1 to this report
and the foregoing description of the terms of the Warrants is qualified in its entirety by reference to such exhibit. A copy
of the opinion of Fenwick & West LLP, relating to the validity of the Units in connection with the Offering, is filed
as Exhibit 5.1 to this Current Report on Form 8-K.
On August 26, 2020, CohBar issued a
press release announcing the pricing of the Offering. A copy of the press release is filed as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
The following exhibit is furnished herewith and this list is
intended to constitute the exhibit index:
Forward-Looking Statements
This Current Report on Form 8-K contains
forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities
laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding
the expected net proceeds of the Offering and the anticipated use of proceeds of the Offering, are forward-looking statements
that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking
statements. Such risks and uncertainties include, among others, the risks identified in CohBar’s filings with the SEC, including
its Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the SEC on August 13, 2020, the prospectus
supplement related to the Offering, and subsequent filings with the SEC. Any of these risks and uncertainties could materially
and adversely affect CohBar’s results of operations, which would, in turn, have a significant and adverse impact on CohBar’s
stock price. CohBar cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date
they are made. CohBar undertakes no obligation to update publicly any forward-looking statements to reflect new information, events
or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
Signature
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
COHBAR, INC.
|
|
(Registrant)
|
|
|
August 26, 2020
|
By:
|
/s/
Jeffrey F. Biunno
|
(Date)
|
|
Jeffrey F. Biunno
Chief Financial Officer
|
2
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Feb 2024 to Mar 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Mar 2023 to Mar 2024